DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial

Information source: State University of New York - Upstate Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alcohol Dependence; Veterans

Intervention: Injectable Naltrexone (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: State University of New York - Upstate Medical University

Official(s) and/or principal investigator(s):
Steven L Batki, M.D., Principal Investigator, Affiliation: Executive Director VA Center for Integrated Healthcare, Syracuse VA Medical Center

Summary

The goal of the proposed project is to improve the primary care treatment of veterans with alcohol dependence. Alcohol dependence is a common behavioral health problem among veterans treated in VA primary care clinics. However, assessment and treatment of alcohol dependence in primary care remains problematic. Assessment of veterans with positive alcohol use screens may not always be completed and referrals to specialty care may not always be made. Moreover, the use of medications for alcohol dependence among veterans is rare, despite VA treatment guidelines that recommend such use. Finally, when medications are prescribed, patients may have difficulties with adherence. The primary aim of this study is to assess the feasibility of long-acting injectable naltrexone provided through primary care (LAN/PC) versus long-acting injectable naltrexone in the specialized chemical dependence clinic (LAN/CDC). The secondary aim is to obtain preliminary assessments of the relative effectiveness of long-acting injectable naltrexone in primary care versus in the chemical dependence clinic.

Clinical Details

Official title: Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Primary Outcomes: Feasibility of an injectable naltrexone study in the primary care setting.

Secondary outcome: Secondary Outcome: Effectiveness of long-acting injectable naltrexone in primary care versus in the chemical dependence clinic.

Eligibility

Minimum age: 18 Years. Maximum age: 69 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Participants must be males or non-pregnant females between the ages of 18 and 69 who

are receiving their primary medical care at the Syracuse VAMC.

- Participants must meet DSM-IV diagnostic criteria for current alcohol dependence.

- Participants must report drinking within the thirty days prior to study entry.

- Participants must receive approval from their primary care provider for study

participation.

- Participants must be willing to consider accepting at least one of the two treatment

conditions. Exclusion Criteria:

- Participants with a current DSM-IV diagnosis of current opioid abuse or dependence,

or in opioid withdrawal

- AST level is greater than 3 times the upper limit of the normal range

- Participants with a medical condition requiring opioid medication or a severe allergy

to naltrexone

- Participants who received outpatient treatment at the Syracuse VA Chemical Dependence

Clinic in the past 90 days

- Any unstable medical or psychiatric conditions in the judgment of the principal

investigator or the participants primary care provider

Locations and Contacts

Syracuse VAMC, Syracuse, New York 13210, United States
Additional Information

Starting date: October 2006
Last updated: October 21, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017